

Dry (Atrophic) Macular Degeneration Therapeutic and Drug Pipeline Review H2

Global Dry (Atrophic) Macular Degeneration Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, February 17, 2017

[/EINPresswire.com/](http://EINPresswire.com/) -- The report provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/535862-age-related-macular-degeneration-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews pipeline therapeutics for Age Related Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental

activities

- The report reviews key players involved Age Related Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Age Related Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Age Related Macular Degeneration Overview 9

Therapeutics Development 10

Age Related Macular Degeneration - Therapeutics under Development by Companies 12

Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 23

Age Related Macular Degeneration - Pipeline Products Glance 24

Age Related Macular Degeneration - Products under Development by Companies 28

Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 40

Age Related Macular Degeneration - Companies Involved in Therapeutics Development 41

Age Related Macular Degeneration - Therapeutics Assessment 157

Drug Profiles 172

Age Related Macular Degeneration - Recent Pipeline Updates 436

Age Related Macular Degeneration - Dormant Projects 535

Age Related Macular Degeneration - Discontinued Products 549

Age Related Macular Degeneration - Product Development Milestones 550

Appendix 557

Access Report @ <https://www.wiseguyreports.com/reports/535862-age-related-macular-degeneration-pipeline-review-h1-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.